[Ten-case report on primary cervical lymphoma].
OBJECTIVE
Clinical feature, treatment and prognosis of primary cervical lymphoma: are retrospectively analysied.


RESULTS
The disease is rare, comprising about 0.9% of all primary cervical malignancies. The average age was 43.6 years. Seven cases had history of familial carcinoma. The complaints: abnormal vaginal bleeding and/or vaginal discharge. The usual pattern of growth was endophytic or polypoid. By FIGO cervical cancer, staging system, there were 8/10 stage I b, 1/10 stage II b and 1/10 stage IV. Histologically all were NHL, B cell lesions(7/10) were the diffuse, cleaved or cleaved-noncleaved cell type. Combination of surgery and chemotherapy were used for 9 of these 10 patients. The follow-up period was 3-66 months. Only one patient had relapse 41 months after the treatment while, others (9/10) survived with no evidence of the disease.


CONCLUSIONS
The prognosis is favorable if cervical lymphoma is discovered early and treated properly.
Sun
M
M
Department of Gynecological Oncology, Shanghai Medical University.
Cao
J
J
Zhang
G
G
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001918:Brachytherapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D012189:Retrospective Studies; D002583:Uterine Cervical Neoplasms / Q000628:therapy*; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone